These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34226630)

  • 1. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases.
    Fujii H; Fukumoto S; Enomoto M; Uchida-Kobayashi S; Kimura T; Tamori A; Nadatani Y; Takashima S; Nishimoto N; Kawada N
    Sci Rep; 2021 Jul; 11(1):13844. PubMed ID: 34226630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Tamaki N; Imajo K; Sharpton S; Jung J; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    Hepatology; 2022 Mar; 75(3):661-672. PubMed ID: 34496054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    Anand A; Elhence A; Vaishnav M; Singh AA; Rajput MS; Banyal V; Jindal V; Pathak P; Kumar P; Nayak B; Yadav R; Das P; Garg H; Agarwal L; Aggarwal S; Kumar R; Shalimar
    J Gastroenterol Hepatol; 2021 May; 36(5):1309-1316. PubMed ID: 33232525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.
    Chaidez A; Pan Z; Sundaram SS; Boster J; Lovell M; Sokol RJ; Mack CL
    Hepatol Commun; 2022 Nov; 6(11):3015-3023. PubMed ID: 36069338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
    Cengiz M; Ozenirler S
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.
    Sumida Y; Yoneda M; Hyogo H; Itoh Y; Ono M; Fujii H; Eguchi Y; Suzuki Y; Aoki N; Kanemasa K; Fujita K; Chayama K; Saibara T; Kawada N; Fujimoto K; Kohgo Y; Yoshikawa T; Okanoue T;
    BMC Gastroenterol; 2012 Jan; 12():2. PubMed ID: 22221544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
    Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
    Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease.
    Shin HK; Park JH; Yu JH; Jin YJ; Suh YJ; Lee JW; Kim W;
    Sci Rep; 2021 Sep; 11(1):18004. PubMed ID: 34504179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
    Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
    J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.